Entrada Therapeutics (TRDA) Other Accumulated Expenses (2020 - 2021)
Entrada Therapeutics (TRDA) recorded quarterly Other Accumulated Expenses of $485000.0 in Q4 2021, up 47.87% quarter-over-quarter from $328000.0 in Q3 2021, and up 321.74% on a YoY basis from $115000.0 in Q4 2020.
Entrada Therapeutics (TRDA) Other Accumulated Expenses (2020 - 2021) Analysis & Trends
Entrada Therapeutics' Other Accumulated Expenses history runs 2 years deep, the most recent figure standing at $485000.0 for Q4 2021.
- In Q4 2021, Other Accumulated Expenses rose 321.74% year-over-year to $485000.0; the TTM figure through Dec 2021 stood at $485000.0 (up 321.74% YoY), while the FY2021 annual figure was $485000.0, up 321.74% from the prior year.
- Other Accumulated Expenses was $485000.0 for Q4 2021 at Entrada Therapeutics, up from $328000.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $485000.0 in Q4 2021 to a low of $115000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Entrada Therapeutics | 295.36 Mn | 295.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 485,000.00 |
| Sep 30, 2021 | 328,000.00 |
| Dec 31, 2020 | 115,000.00 |